BIAFWライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (28 6月 2024 @ 05:00):
Our systems believe the stock currently is undervalued by 0.52% compare to its pairs and should correct upwards.

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment...

Stats
本日の出来高	1 000
平均出来高	0
時価総額	3.50M
EPS	$-0.200 ( Q1 \| 2024-05-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0 (Sector) 42.63 (Industry) 39.71
ATR14	$0 (0.00%)

AWH 13.74%

BIAF 1.41%

BIAFW -52.29%

INBS 1.59%

LMDXW 0.00%

PRE -1.33%

PRENW -2.11%

Insider Trading

Date	Person	Action	Amount	type
2023-12-01	Platt Jamie	Buy	0
2023-09-18	Joyce Roby	Buy	0	Common Stock
2021-11-22	Joyce Roby	Buy	14 285	Warrant
2023-09-18	Reveles Xavier Trinidad	Sell	0	Common Stock
2021-08-26	Reveles Xavier Trinidad	Sell	2 142	Stock Option (Right to Buy)

INSIDER POWER
64.00
Last 96 transactions
Buy: 1 799 574 \| Sell: 997 504

相関 (AI algo v.1.1b): Undervalued: 0.52% $0.302 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

bioAffinity Technologies, 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

bioAffinity Technologies, 財務諸表

Annual	2023
収益:	$2.53M
総利益:	$542 023 (21.40 %)
EPS:	$-0.910

FY	2023
収益:	$2.53M
総利益:	$542 023 (21.40 %)
EPS:	$-0.910

FY	2022
収益:	$4 803.00
総利益:	$4 336.00 (90.28 %)
EPS:	$-1.810

Financial Reports:

No articles found.

bioAffinity Technologies, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

bioAffinity Technologies,

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.